Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.jbiomech.2021.110235 http://scihub22266oqcxt.onion/10.1016/j.jbiomech.2021.110235 33486262!7832952!33486262     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       J+Biomech 2021 ; 117 (ä): 110235 Nephropedia Template TP {{tp|p=33486262|t=2021. Microfluidic detection of human diseases: From liquid biopsy to COVID-19 diagnosis |pdf=|usr=}}{{33486262}} gab.com Text Microfluidic detection of human diseases: From liquid biopsy to COVID-19 diagnosis JO: J Biomech http://www.kidney.de/pget.php?&tw=1&pmid=33486262 #FOAvip Microfluidic devices can be thought of as comprising interconnected miniaturized compartments performing multiple experimental tasks individually or in parallel in an integrated fashion. Due to its small size, portability, and low cost, attempts have been made to incorporate detection assays into microfluidic platforms for diseases such as cancer and infection. Some of these technologies have served as point-of-care and sample-to-answer devices. The methods for detecting biomarkers in different diseases usually share similar principles and can conveniently be adapted to cope with arising health challenges. The COVID-19 pandemic is one such challenge that is testing the performance of both our conventional and newly-developed disease diagnostic technologies. In this mini-review, we will first look at the progress made in the past few years in applying microfluidics for liquid biopsy and infectious disease detection. Following that, we will use the current pandemic as an example to discuss how such technological advancements can help in the current health challenge and better prepare us for future ones. Twit Text FOAVip Microfluidic detection of human diseases: From liquid biopsy to COVID-19 diagnosis ????J Biomech http://www.kidney.de/pget.php?&tw=1&pmid=33486262 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33486262 #FOAvip English Wikipedia <ref>{{Cite pmid|33486262}}</ref> Microfluidic detection of human diseases: From liquid biopsy to COVID-19 diagnosis #MMPMID33486262 Jiang K; Jokhun DS; Lim CT J Biomech 2021[Mar]; 117 (ä): 110235 PMID33486262show ga Microfluidic devices can be thought of as comprising interconnected miniaturized compartments performing multiple experimental tasks individually or in parallel in an integrated fashion. Due to its small size, portability, and low cost, attempts have been made to incorporate detection assays into microfluidic platforms for diseases such as cancer and infection. Some of these technologies have served as point-of-care and sample-to-answer devices. The methods for detecting biomarkers in different diseases usually share similar principles and can conveniently be adapted to cope with arising health challenges. The COVID-19 pandemic is one such challenge that is testing the performance of both our conventional and newly-developed disease diagnostic technologies. In this mini-review, we will first look at the progress made in the past few years in applying microfluidics for liquid biopsy and infectious disease detection. Following that, we will use the current pandemic as an example to discuss how such technological advancements can help in the current health challenge and better prepare us for future ones. |*COVID-19 Testing[MESH] |*Point-of-Care Testing[MESH] |Biomarkers[MESH] |COVID-19/*diagnosis[MESH] |Circulating Tumor DNA[MESH] |Exosomes[MESH] |Humans[MESH] |Lab-On-A-Chip Devices[MESH] |Liquid Biopsy/*methods[MESH] |Machine Learning[MESH] |Microfluidics/*methods[MESH] |Neoplasms/diagnosis[MESH]Microfluidic detection of human diseases: From liquid biopsy to COVID-(epmc).pdf DeepDyve Pubget Overpricing